BACKGROUND: There are no clear criteria established for treating a @entity157 ( @entity157 ). To elucidate the clinical features of affected @entity1 , we examined prognosis and therapy choices. MATERIALS/METHODS: We enrolled 67 @entity1 treated for a @entity157 ( @entity3531 44, @entity97 5, @entity97 + @entity3531 1, @entity167 2, others 15; na  ve @entity157 34, recurrent 33) from 2000 to 2013, and investigated their clinical background and prognosis. RESULTS: @entity1349 ( @entity1349 ) for all cases was 4 months. For @entity1 who survived for more than 1 year after @entity397 , the percentages of @entity1 -Pugh C and positive for @entity715 ( @entity715 )/extrahepatic @entity3 were less than for those who died within 1 year. @entity1 -Pugh classification (A:B:C=14:15:5 vs. 4:9:20, P<0.001) was better, while the percentage of @entity1 with @entity5 was lower [19/34 (55.9%) vs. 29/33 (87.9%), respectively; P<0.001] in the na  ve group. The 1- and 3-year survival rates were better in the na  ve as compared to the recurrent group (60.6% and 33.3% vs. 12.6% and 0%, respectively; P<0.01). @entity1349 according to modified TNM stage (UICC 7th) calculated after exclusion of T4 factor of @entity397 , stage I was better than others (22.7 vs. (II) 2.2, (III) 1.2, and (IV) 0.7 months) (P=0.010). CONCLUSION: In @entity1 with a @entity157 , especially those with a @entity5 , and without decompensated @entity1575 and @entity715 /extrahepatic @entity3 , better prognosis can be expected with curative treatment. The present na  ve group included more of such cases than the recurrent group, indicating the effectiveness of curative therapy.

Prognosis and therapy for XXXX : Problems with staging and treatment strategy.

@entity1 :: ('9606', 'Species') :: ['Child', 'patients'] @entity97 :: ('10407', 'Species') :: ['HBV'] @entity3531 :: ('11096', 'Species') :: ['HCV'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol'] @entity5 :: ('MESH:D009369', 'Disease') :: ['multiple tumors', 'single tumor'] @entity397 :: ('MESH:D012421', 'Disease') :: ['rupture'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['ruptured hepatocellular carcinoma', 'HCC', 'ruptured HCC'] @entity715 :: ('MESH:D013927', 'Disease') :: ['PVTT', 'portal vein tumor thrombosis'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['Median survival time', 'MST']
@entity157 :: (MESH:D006528,Disease) :: ['ruptured hepatocellular carcinoma']
